Studies have shown that p38 MAPK increases the expression of various metalloproteinases in CFs through diverse mechanisms [46, 47] and reduces that of tissue metalloproteinase inhibitor-1 [48]. This evidence concerns the gene TIMP1 and myalgic encephalomeyelitis/chronic fatigue syndrome.